Stockscreener 앱 받기
111.30
0.70%
-0.78
시간 외 거래:
111.30
전일 마감가:
$112.08
열려 있는:
$111.25
하루 거래량:
893.67K
Relative Volume:
0.99
시가총액:
$6.73B
수익:
$3.99B
순이익/손실:
$463.16M
주가수익비율:
15.68
EPS:
7.1
순현금흐름:
$1.10B
1주 성능:
-3.65%
1개월 성능:
+1.99%
6개월 성능:
-7.47%
1년 성능:
-1.48%
1일 변동 폭
$109.87
$112.32
1주일 범위
$105.00
$117.39
52주 변동 폭
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
명칭
Jazz Pharmaceuticals Plc
전화
353-1-634-7800
주소
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
JAZZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
111.30 | 6.41B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-15 | 개시 | Deutsche Bank | Buy |
| 2025-03-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-26 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Buy |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-11-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-09-29 | 개시 | Raymond James | Mkt Perform |
| 2023-06-12 | 재개 | Wells Fargo | Equal Weight |
| 2022-12-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-11-19 | 재개 | Goldman | Buy |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-10-05 | 개시 | Citigroup | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-05-19 | 재개 | JP Morgan | Overweight |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | 개시 | Jefferies | Buy |
| 2020-03-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Neutral |
| 2019-08-21 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Peer Perform |
| 2018-11-08 | 재확인 | B. Riley FBR | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | 재확인 | H.C. Wainwright | Neutral |
| 2018-03-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance - MSN
Using flow based indicators on Jazz Pharmaceuticals plcTechnical Analysis of Growth Stock Opportunities - Newser
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
Jazz Pharma wins FDA nod for Modeyso against rare brain tumor - MSN
Jazz Pharmaceuticals gets EU nod for Ziihera - MSN
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock - Yahoo Finance
How to integrate Jazz Pharmaceuticals plc into portfolio analysis tools - Newser
Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted - insights.citeline.com
FDA Grants Accelerated Approval to Dordaviprone For Diffuse Midline Glioma - Pharmacy Times
Jazz Pharma wins FDA nod for brain tumor drug (JAZZ:NASDAQ) - Seeking Alpha
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2025 Earnings Call Transcript - Insider Monkey
FDA approval of Modeyso for glioma - The Pharma Letter
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results - TradingView
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut - MSN
Beyond the Balance Sheet: What SWOT Reveals About Jazz Pharmaceu - GuruFocus
Chimerix buyout a win for Jazz with FDA nod for rare glioma drug - BioWorld MedTech
US FDA approves Jazz Pharma's drug for rare brain tumor - Reuters
Rising Star: Quinn Emanuel's Frank Calvosa - Law360
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma - Morningstar
Jazz Pharmaceuticals plc SEC 10-Q Report - TradingView
What data driven models say about Jazz Pharmaceuticals plc’s futureFree Triple Digit Return Stock Predictions - Newser
Jazz Pharmaceuticals plc 2025 Q2ResultsEarnings Call Presentation (NASDAQ:JAZZ) - Seeking Alpha
Jazz: Q2 Earnings Snapshot - Greenwich Time
Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... - Yahoo Finance
Jazz Pharmaceuticals plc Earnings Report Breakdown: What Investors Should KnowTechnical Analysis of Growth Stock Opportunities - Newser
Using data tools to time your Jazz Pharmaceuticals plc exitFree Wealth Building Stock Market Ideas - Newser
Jazz Pharmaceuticals Reports Q2 2025 Results and CEO Transition - TipRanks
Jazz Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Jazz Pharmaceuticals Sticks To Its Game Plan Despite Setbacks - Finimize
Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Jazz Pharmaceuticals PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Jazz Pharmaceuticals misses on Q2 earnings, shares fall By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals misses on Q2 earnings, shares fall - Investing.com
Jazz Pharma earnings missed by $0.63, revenue topped estimates - Investing.com South Africa
Jazz Pharmaceuticals Q2 revenue up 2% - MarketScreener
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Posts Q2 Adjusted Loss $8.25 per Share, vs. FactSet Est Loss of $7.61 - MarketScreener
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance - PR Newswire
Narcolepsy Market to Reach New Heights in Growth by 2034, - openPR.com
Narcolepsy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts| Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical - Barchart.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) investors are sitting on a loss of 25% if they invested three years ago - Yahoo Finance
How Jazz Pharmaceuticals plc stock reacts to Fed policy changesSwing Entry Insight With Forecast Accuracy - Newser
What MACD signals say about Jazz Pharmaceuticals plcOversold Opportunity Scanner with RSI Data - Newser
Jazz Pharmaceuticals (JAZZ) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results - MSN
How volatile is Jazz Pharmaceuticals plc stock compared to the marketTrack top-performing stocks effortlessly - Jammu Links News
What are the latest earnings results for Jazz Pharmaceuticals plcBuild a winning investment strategy today - Jammu Links News
How does Jazz Pharmaceuticals plc generate profit in a changing economyUnlock real-time trading signals for gains - Jammu Links News
Why is Jazz Pharmaceuticals plc stock attracting strong analyst attentionFree Stock Market Mentorship - Jammu Links News
Does Jazz Pharmaceuticals plc stock perform well during market downturnsBreakthrough stock performance - Jammu Links News
Jazz Pharmaceuticals Plc (JAZZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):